首页> 外文OA文献 >Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation
【2h】

Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation

机译:Long-term results of intensity-modulated radiotherapy concomitant with chemotherapy for hypopharyngeal carcinoma aimed at laryngeal preservation

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

[[abstract]]BackgroundThe objective of this retrospective study is to investigate laryngeal preservation and long-term treatment results in hypopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) combined with chemotherapy.MethodsTwenty-seven patients with hypopharyngeal carcinoma (stage II-IV) were enrolled and underwent concurrent chemoradiotherapy. The chemotherapy regimens were monthly cisplatin and 5-fluorouracil for six patients and weekly cisplatin for 19 patients. All patients were treated with IMRT with simultaneous integrated boost technique. Acute and late toxicities were recorded based on CTCAE 3.0 (Common Terminology Criteria for Adverse Events).ResultsThe median follow-up time for survivors was 53.0 months (range 36-82 months). The initial complete response rate was 85.2%, with a laryngeal preservation rate of 63.0%. The 5-year functional laryngeal, local-regional control, disease-free and overall survival rates were 59.7%, 63.3%, 51.0% and 34.8%, respectively. The most common greater than or equal to grade 3 acute and late effects were dysphagia (63.0%, 17 of 27 patients) and laryngeal stricture (18.5%, 5 of 27 patients), respectively. Patients belonging to the high risk group showed significantly higher risk of tracheostomy compared to the low risk group (p = 0.014).ConclusionsAfter long-term follow-up, our results confirmed that patients with hypopharyngeal carcinoma treated with IMRT concurrent with platinum-based chemotherapy attain high functional laryngeal and local-regional control survival rates. However, the late effect of laryngeal stricture remains a problem, particularly for high risk group patients.
机译:[[摘要]]背景这项回顾性研究的目的是研究经调强放疗(IMRT)联合化学疗法治疗的下咽癌的喉镜保存和长期治疗效果。方法27例下咽癌(II-IV期) )并同时进行放化疗。化疗方案为6例患者使用每月顺铂和5-氟尿嘧啶,19例患者使用每周使用顺铂。所有患者均接受IMRT联合同步增强技术治疗。根据CTCAE 3.0(不良事件通用术语标准)记录急性和晚期毒性。结果幸存者的中位随访时间为53.0个月(36-82个月)。初始完全缓解率为85.2%,喉保存率为63.0%。五年功能性喉,局部控制,无病生存率和总生存率分别为59.7%,63.3%,51.0%和34.8%。大于或等于3级急性和晚期最常见的症状分别是吞咽困难(63.0%,27例中的17例)和喉管狭窄(18.5%,27例中的5例)。与低风险组相比,高风险组患者的气管切开术风险显着更高(p = 0.014)。结论长期随访后,我们的结果证实了IMRT联合铂类化疗治疗的下咽癌患者获得高功能性喉癌和局部区域控制的生存率。然而,喉狭窄的后期效果仍然是一个问题,特别是对于高危人群。

著录项

  • 作者

    Wen-Shan Liu;

  • 作者单位
  • 年度 2011
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号